Show simple item record

dc.contributor.authorFuller, H.
dc.contributor.authorRace, Amanda D.
dc.contributor.authorFenton, H.
dc.contributor.authorBurke, L.
dc.contributor.authorDowning, A.
dc.contributor.authorWilliams, E.A.
dc.contributor.authorRees, C.J.
dc.contributor.authorBrown, L.C.
dc.contributor.authorLoadman, Paul
dc.contributor.authorHull, M.A.
dc.date.accessioned2023-10-05T11:18:36Z
dc.date.accessioned2023-10-06T08:09:17Z
dc.date.available2023-10-05T11:18:36Z
dc.date.available2023-10-06T08:09:17Z
dc.date.issued2023-05
dc.identifier.citationFuller H, Race AD, Fenton H et al (2023) Plasma and rectal mucosal oxylipin levels during aspirin and eicosapentaenoic acid treatment in the seAFOod polyp prevention trial. Prostaglandins Leukotrienes and Essential Fatty Acids. 192. 102570.en_US
dc.identifier.urihttp://hdl.handle.net/10454/19605
dc.descriptionYesen_US
dc.description.abstractAspirin and eicosapentaenoic acid (EPA) have colorectal polyp prevention activity, alone and in combination. This study measured levels of plasma and rectal mucosal oxylipins in participants of the seAFOod 2 × 2 factorial, randomised, placebo-controlled trial, who received aspirin 300 mg daily and EPA 2000 mg free fatty acid, alone and in combination, for 12 months. Resolvin (Rv) E1, 15-epi-lipoxin (LX) A4 and respective precursors 18-HEPE and 15-HETE (with chiral separation) were measured by ultra-high performance liquid chromatography-tandem mass spectrometry in plasma taken at baseline, 6 months and 12 months, as well as rectal mucosa obtained at trial exit colonoscopy at 12 months, in 401 trial participants. Despite detection of S- and R- enantiomers of 18-HEPE and 15-HETE in ng/ml concentrations, RvE1 or 15‑epi-LXA4 were not detected above a limit of detection of 20 pg/ml in plasma or rectal mucosa, even in individuals randomised to both aspirin and EPA. We have confirmed in a large clinical trial cohort that prolonged (12 months) treatment with EPA is associated with increased plasma 18-HEPE concentrations (median [inter-quartile range] total 18-HEPE 0.51 [0.21-1.95] ng/ml at baseline versus 0.95 [0.46-4.06] ng/ml at 6 months [Pen_US
dc.language.isoenen_US
dc.rights(c) 2023 The Authors. This is an Open Access article distributed under the Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/)en_US
dc.subjectColorectal canceren_US
dc.subjectColorectal polypen_US
dc.subjectHEPEen_US
dc.subjectHETEen_US
dc.subjectLipoxinen_US
dc.subjectOxylipinen_US
dc.subjectResolvinen_US
dc.titlePlasma and rectal mucosal oxylipin levels during aspirin and eicosapentaenoic acid treatment in the seAFOod polyp prevention trialen_US
dc.status.refereedYesen_US
dc.date.Accepted2023-03-21
dc.date.application2023-03-23
dc.typeArticleen_US
dc.type.versionPublished versionen_US
dc.identifier.doihttps://doi.org/10.1016/j.plefa.2023.102570
dc.rights.licenseCC-BYen_US
dc.date.updated2023-10-05T11:18:38Z
refterms.dateFOA2023-10-06T08:09:50Z
dc.openaccess.statusopenAccessen_US


Item file(s)

Thumbnail
Name:
Fuller2023.pdf
Size:
1.802Mb
Format:
PDF
Description:
fuller_et_al_2023

This item appears in the following Collection(s)

Show simple item record